# US 2022/0017489 A1 · Solid dispersions for treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0017489 A1
- Document ID: US20220017489A1
- Status: Published application
- Kind: A1
- Application number: 17/290,224
- Filed: 2019-11-01
- Published: 2022-01-20
- Earliest claimed: 2018-11-02
- Assignees: Celgene Corporation
- Applicants: Celgene Corporation
- Inventors: Eric A. Fromme; Kevin J. Klopfer
- Web page: https://patentgrep.com/patent/US20220017489A1

## CPC

- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- C07D 401/14: containing three or more hetero rings
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 35/02: specific for leukemia
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Provided herein are amorphous solid dispersions comprising Compound 1 and a polymer. Pharmaceutical compositions comprising the solid dispersions and methods for treating, preventing and managing cancer are also disclosed.

## Claims

### Claim 1

A solid dispersion comprising 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, prodrug, or clathrate thereof (Compound 1) dispersed in a solid matrix that comprises a polymer.

### Claim 2 (depends on 1)

The amorphous solid dispersion of claim 1, wherein the polymer is selected from the group consisting of a cellulose ester, cellulose ether, polyalkylene oxide, polyacrylate, polymethacrylate, N-vinyl lactam polymer, N-vinyl lactam copolymer, polyacrylamide, vinyl acetate polymer, graft copolymer of polyethylene glycol, polyvinyl caprolactam, polyvinyl acetate, oligosaccharide, and polysaccharide.

### Claim 3 (depends on 1)

The amorphous solid dispersion of claim 1, wherein the polymer is selected from the group consisting of hydroxyethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, methacrylate copolymer, polyethylene glycol 6000, polyvinylpyrrolidone K30, poly(1-vinylpyrrolidone-co-vinyl acetate, polyoxyethylene-polyoxypropylene copolyme, D-α-tocopherol polyethylene glycol 1000 succinate, acrylic polymer, polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer, polyvinyl alcohol/polyethylene glycol graft copolymer, polyvinyl acetate phthalate, and methyl cellulose.

### Claim 4 (depends on 1)

The amorphous solid dispersion of claim 1, wherein the polymer is selected from the group consisting of acrylic polymer, hydroxypropyl methyl cellulose and methyl cellulose.

### Claim 5 (depends on 1)

The amorphous solid dispersion of claim 1, wherein the polymer is hydroxypropyl methyl cellulose.

### Claim 6 (depends on 1)

The amorphous solid dispersion of claim 1, wherein Compound 1 is present in an amount of from about 5% to about 75% by weight of the amorphous solid dispersion.

### Claim 7 (depends on 6)

The amorphous solid dispersion of claim 6, wherein Compound 1 is present in an amount of from about 5%, 10%, 15%, 20%, 25%, 30%, 40% or 50% by weight of the amorphous solid dispersion.

### Claim 8 (depends on 6)

The amorphous solid dispersion of claim 6, wherein 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol is present in an amount of from about 10%, 20%, 25%, or 50% by weight of the amorphous solid dispersion.

### Claim 9 (depends on 6)

The amorphous solid dispersion of claim 6, wherein 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol methanesulfonate is present in an amount of from about 10%, 20%, 25%, or 50% by weight of the amorphous solid dispersion.

### Claim 10 (depends on 1)

The amorphous solid dispersion of claim 1, wherein Compound 1 is substantially non-crystalline.

### Claim 11 (depends on 1)

A pharmaceutical composition comprising the amorphous solid dispersion of claim 1, and a pharmaceutically acceptable excipient.

### Claim 12 (depends on 1)

A method of treating a disease selected from a hematological malignancy and a solid tumor, each characterized by the presence of a mutant allele of IDH2, comprising administering to a subject having the disease, a therapeutically effective amount of the amorphous solid dispersion of claim 1.

### Claim 13 (depends on 12)

The method of claim 12, wherein the disease is characterized by the presence of a mutant allele of IDH2 and the absence of a mutant allele of FLT3.

### Claim 14 (depends on 12)

The method of claim 12, wherein the disease is characterized by the presence of a mutant allele of IDH2 and the absence of a mutant allele of NRAS.

### Claim 15 (depends on 1)

The method of claim 1, wherein the disease is a hematological malignancy.

### Claim 16 (depends on 1)

The method of claim 1, wherein the hematological malignancy is selected from acute myelogenous leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia myeloid sarcoma, multiple myeloma, lymphoma, angioimmunoblastic T-cell lymphoma, blastic plasmacytoid dendritic cell neoplasm and myeloproliferative neoplasm, each characterized by the presence of a mutant allele of IDH2.

### Claim 17 (depends on 1)

The method of claim 1, wherein the hematological malignancy is acute myelogenous leukemia.

### Claim 18 (depends on 16)

The method of claim 16, wherein the disease is myelodysplastic syndrome.

### Claim 19 (depends on 16)

The method of claim 16, wherein the disease is characterized by the presence of a mutant allele of IDH2 and a mutant allele of at least one second gene, wherein the second gene is selected from the group consisting of ASXL1 and SRSF2.

### Claim 20 (depends on 16)

The method of claim 16, wherein the disease is characterized by the presence of a mutant allele of IDH2 and the absence of a mutant allele of at least one other gene, wherein the other gene is selected from the group consisting of KRAS, TP53, SETBP1, U2AF1, TCF3, STAG2, NRAS, JAK2 and BRAF.

### Claim 21 (depends on 1)

The method of claim 1, wherein the solid tumor is selected from glioma, melanoma, chondrosarcoma, and cholangiocarcinoma, each characterized by the presence of a mutant allele of IDH2.

### Claim 22 (depends on 1)

The method of claim 1, wherein the disease is relapsed or refractory.

### Claim 23 (depends on 1)

The method of claim 1, further comprising administering a second active agent.

### Claim 24 (depends on 1)

The method of claim 1, wherein the subject is a pediatric patient.

### Claim at position 25

25-37. (canceled)

### Claim 38 (depends on 1)

A process for preparing an amorphous solid dispersion of claim 1, comprising (a) providing a solution of Compound 1 and the polymer in a solvent system; and (b) removing the solvent to provide the amorphous solid dispersion.

### Claim 39 (depends on 38)

The process of claim 38, wherein the polymer is hydroxypropyl methyl cellulose.

### Claim 40 (depends on 38)

The process of claim 38, wherein the solvent system comprises methanol, water, dichloromethane, tetrahydrofuran, acetone, trifluoroethanol, ethanol, or a mixture thereof.

### Claim 41 (depends on 38)

The process of claim 38, wherein the solvent system comprises dichloromethane, a mixture of tetrahydrofuran and water, a mixture of methanol and water, a mixture of acetone and methanol, a mixture of 2,2,2-trifluoroethanol and water, or a mixture of chloroform and ethanol.

### Claim 42 (depends on 38)

The process of claim 38, wherein the solvent is removed by freeze evaporation.

### Claim 43 (depends on 38)

The process of claim 38, wherein the solvent is removed by spray drying.
